TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer - Pfizer

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer    Pfizer ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win    Fierce Pharma ASCO26: Talzenna-Xtandi regimen halves risk of progression, death in prostate cancer    FirstWord Pharma Pfizer combo sees 77% of advanced prostate cancers progression-free at 3 years    Stock Titan Pfizer says Talzenna plus Xtandi improves radiographic progression-free survival by over 50% in metastatic prostate cancer    marketscreener.com

Original source: Google News